Omadacycline and eravacycline are newly approved tetracycline analogues with excellent activity against a broad spectrum of Gram-positive and Gram-negative microorganisms; however, no data are available regarding Helicobacter pylori. The susceptibility of 201 clinical isolates of H. pylori collected in China to omadacycline, eravacycline, and the comparator tetracycline was determined by an agar dilution method. They showed greater activity than tetracycline. The MIC values of omadacycline, eravacycline, and tetracycline were 0.125/0.25 μg/mL, 0.063/0.125 μg/mL, and 0.25/1 μg/mL, respectively. Omadacycline and eravacycline were potent in vitro against all the isolates tested, including tetracycline-resistant strains, and warrant further investigation as potential antibiotics for H. pylori treatment.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.diagmicrobio.2020.115129 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Discordant Susceptibilities of Enterobacterales to Different Tetracycline Classes.
Cureus
December 2024
Internal Medicine, University of Maryland Medical Center, Baltimore, USA.
When bacteria are tetracycline- or doxycycline-resistant, the ability of these bacteria to be susceptible to the other tetracyclines is not well defined. Consequently, gaining knowledge about the ability to infer Enterobacterales susceptibility to minocycline and third-generation tetracycline antibiotics from surrogates is vital. In this study, we show that tigecycline may be a reasonable surrogate from which clinicians can infer omadacycline and eravacycline susceptibilities, even in the presence of doxycycline and tetracycline resistance.
View Article and Find Full Text PDFActivity of cefiderocol in combination with tetracycline analogues against carbapenem-resistant Acinetobacter baumannii.
J Antibiot (Tokyo)
December 2024
Department of Respiratory Medicine, An Qiu People's Hospital, An Qiu, China.
Therapeutic options for carbapenem-resistant Acinetobacter baumannii (CA-AB) are quite limited. Cefiderocol, a novel siderophore cephalosporin, has shown potent in vitro activity against CR-AB, and new tetracycline analogues such as eravacycline and omadacycline have been available in recent years. However, the synergism of cefiderocol with tetracycline analogues against CR-AB has not been well investigated.
View Article and Find Full Text PDFActivity and resistance mechanisms of the third generation tetracyclines tigecycline, eravacycline and omadacycline against nationwide Spanish collections of carbapenemase-producing Enterobacterales and Acinetobacter baumannii.
Biomed Pharmacother
December 2024
Servicio de Microbiología and Instituto de Investigación Biomédica A Coruña (INIBIC), Complexo Hospitalario Universitario A Coruña (CHUAC), A Coruña, Spain; Ciber de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain.
Introduction: The rise in multidrug-resistant bacteria challenges clinical microbiology. Tigecycline, eravacycline, and omadacycline show promise against carbapenem-resistant Enterobacterales and Acinetobacter baumannii. This study evaluates their activity and resistance mechanisms.
View Article and Find Full Text PDFSystematic analysis of the adverse effects of commonly used clinical tetracycline drugs based on the FAERS database.
Expert Opin Drug Saf
August 2024
Kunming Kingmed Institute for Clinical Laboratory Co. Ltd, Kunming, Yunnan province, China.
Article Synopsis
- Tetracyclines are widely used antibacterial drugs, but their adverse effects (AEs) had not been systematically analyzed until this study, which utilized the FDA's FAERS database from 2004 to 2023.
- The research identified 15,020 cases and calculated signal values for various AEs linked to different tetracycline drugs, with notable findings such as doxycycline causing gastrointestinal issues and minocycline linked to skin pigmentation changes.
- The study highlighted previously unreported AEs like ototoxicity, along with psychiatric effects from doxycycline and concerns related to tumors from minocycline, suggesting that awareness of these risks should be increased among healthcare providers and patients.
Combinations of Antibiotics Effective against Extensively- and Pandrug-Resistant Patient Isolates.
Microorganisms
July 2024
Department of Biomedical Sciences, Cooper Medical School of Rowan University, Camden, NJ 08103, USA.
Infections due to drug-resistant strains are increasing and cause significant morbidity and mortality, especially in hospitalized and critically ill patients. rapidly develops resistance to numerous antibiotics, and antibiotics traditionally used against this deadly pathogen have been failing in recent years, highlighting the need to identify new treatment strategies. Treatment options that have shown promise include revisiting common antibiotics not typically used against , evaluating new antibiotics recently introduced to market, and identifying combinations of antibiotics that display synergistic interactions.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!